

FREDERICK F. BECKER, EDITOR

CANCER

A COMPREHENSIVE TREATISE
ETIOLOGY: Chemical and Physical Carcinogenesis

SECOND EDITION

I

CANCER

1

A COMPREHENSIVE TREATISE

SECOND EDITION

ETIOLOGY: Chemical and Physical Carcinogenesis /

FREDERICK F. BECKER, EDITOR

*University of Texas System Cancer Center
M.D. Anderson Hospital and Tumor Institute
Houston, Texas*

PLENUM PRESS • NEW YORK AND LONDON

Library of Congress Cataloging in Publication Data

Main entry under title:

Cancer: a comprehensive treatise.

Includes bibliographies and indexes.

Contents: v. 1. Etiology, chemical and physical carcinogenesis.

1. Cancer -- Collected works. I. Becker, Frederick F. [DNLM: 1. Neoplasms. QZ 200 C2143]

RC261.C263 1982

616.99'4

81-21050

ISBN 0-306-40701-9

AACR2

©1982 Plenum Press, New York
A Division of Plenum Publishing Corporation
233 Spring Street, New York, N.Y. 10013

All rights reserved

No part of this book may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, microfilming, recording, or otherwise, without written permission from the Publisher

Printed in the United States of America

CANCER

A COMPREHENSIVE TREATISE

1

SECOND EDITION

ETIOLOGY: Chemical and Physical Carcinogenesis

Editorial Board: Joseph R. Bertino *Yale University School of Medicine*

Emmanuel Farber *University of Toronto*

Henry S. Kaplan *Stanford University*

George Klein *Karolinska Institute*

Arthur C. Upton *State University of New York at Stony Brook*

Volume 1 • ETIOLOGY: Chemical and Physical Carcinogenesis

First Edition

Volume 2 • ETIOLOGY: Viral Carcinogenesis

Volume 3 • BIOLOGY OF TUMORS: Cellular Biology and Growth

Volume 4 • BIOLOGY OF TUMORS: Surfaces, Immunology,
and Comparative Pathology

Volume 5 • CHEMOTHERAPY

Volume 6 • RADIOTHERAPY, SURGERY, AND IMMUNOTHERAPY



To Mary Ellen Becker

without whose encouragement and support
this treatise would not have been completed.

Contributors

to Volume 1

ROBERT W. BALDWIN, Cancer Research Campaign Laboratories, University of Nottingham, Nottingham, England

FREDERICK F. BECKER, Department of Anatomic and Research Pathology, M. D. Anderson Hospital and Tumor Institute, University of Texas System Cancer Center, Houston, Texas

ISAAC BERENBLUM, The Weizmann Institute of Science, Rehovot, Israel

K. GERHARD BRAND, Department of Microbiology, University of Minnesota Medical School, Minneapolis, Minnesota

EMMANUEL FARBER, Departments of Pathology and Biochemistry, University of Toronto, Toronto, Ontario, Canada

JACOB FURTH, Institute of Cancer Research and Department of Pathology, Columbia University College of Physicians and Surgeons, New York, New York

VINCENT F. GUINEE, Department of Epidemiology, The University of Texas System Cancer Center, M. D. Anderson Hospital and Tumor Institute, Houston, Texas

W. E. HESTON, Laboratory of Biology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland

ALBRECHT M. KELLERER, Institut für Medizinische Strahlenkunde, University of Würzburg, Würzburg, Federal Republic of Germany

ALFRED G. KNUDSON, JR., The University of Texas Health Science Center at Houston, Graduate School of Biomedical Sciences, Houston, Texas

CORNELIS J. M. MELIEF, Hematology Service, New England Medical Center Hospital, and Department of Medicine, Tufts University School of Medicine, Boston, Massachusetts

PETER C. NOWELL, Department of Pathology, School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania

- MICHAEL POTTER, National Cancer Institute, Laboratory of Cell Biology, Bethesda, Maryland
- MICHAEL R. PRICE, Cancer Research Campaign Laboratories, University of Nottingham, Nottingham, England
- S. RAJALAKSHMI, Department of Pathology, University of Toronto, Toronto, Ontario, Canada
- PREMA M. RAO, Department of Pathology, University of Toronto, Toronto, Ontario, Canada
- JANARDAN K. REDDY, Department of Pathology, Northwestern University Medical School, Chicago, Illinois
- HARALD H. ROSSI, Radiological Research Laboratory, Department of Radiology, Cancer Center/Institute of Cancer Research, Columbia University College of Physicians and Surgeons, New York, New York
- D. S. R. SARMA, Department of Pathology, University of Toronto, Toronto, Ontario, Canada
- ROBERT S. SCHWARTZ, Hematology Service, New England Medical Center Hospital, and Department of Medicine, Tufts University School of Medicine, Boston, Massachusetts
- JOHN B. STORER, Biology Division, Oak Ridge National Laboratory, Oak Ridge, Tennessee
- DONALD J. SVOBODA, Department of Pathology and Oncology, University of Kansas College of Health Sciences, Kansas City, Kansas
- ARTHUR C. UPTON, Health Sciences Center, State University of New York at Stony Brook, Stony Brook, New York
- FREDERICK URBACH, Temple University School of Medicine, Skin and Cancer Hospital, Philadelphia, Pennsylvania
- J. H. WEISBURGER, American Health Foundation, Naylor Dana Institute for Disease Prevention, Valhalla, New York
- G. M. WILLIAMS, American Health Foundation, Naylor Dana Institute for Disease Prevention, Valhalla, New York

Preface

Six years ago when the first edition of this volume appeared as the first of the series, questions were posed in its preface that are as valid today as they were then. In that preface, I proposed the following challenges:

(1) We must identify carcinogenic agents, and by an analysis of their "nature," e.g., structure and physical characteristics, we may better understand their mechanism of action. (2) We must identify crucial interactions between these carcinogens and important macromolecules within the cell, distinguishing those which relate to carcinogenesis from those which are extraneous. (3) We must examine the alterations of cell function induced by these reactions, for it is with an understanding of phenotypic variation that we may know why malignant cells escape from normal homeostatic control. (4) Last, and perhaps of greatest importance, we must define malignancy—define those characteristics of cellular activity that permit the malignant cell to compete so effectively with the normal constituent, which ultimately leads to such destructive events.

Although great strides have been made toward those goals, as evidenced by a number of new chapters and the new information gathered into others, and although the achievement of those goals sometimes appears but a tantalizing experiment away, none have been achieved. For example, several chapters include descriptions of the progress that has been made toward the development of "quick assays." The aggregate of methods they describe is aimed at making available a test or cascade of tests that, in a short time and for reasonable cost, will indicate with a high probability of accuracy whether a given chemical agent would be carcinogenic for man. The socioeconomic implications of such tests should be all too familiar to the reader. In the main, these tests extrapolate from mutation or other cellular alteration to carcinogenicity. By implication, they can cause chemicals of value to be proscribed or they can justify the persistence of a carcinogen in our environment. Additionally, these tests, which utilize organisms ranging from the lowest forms of prokaryotes to human cells in aggregate, may yield information about the type of basic alteration responsible for the initiation (in the broadest sense) of the carcinogenic process.

The overlap of these findings with those described by Rajalakshmi and others is evident. An enormous amount of information has emerged concerning the nature and specificity of intracellular macromolecular interactions by these agents. Their "imprinting" on the cell's genome, the balance of repair and

misrepair, the magnification of the alteration by cell division, and other cellular phenomena are becoming more apparent. Yet all these findings, as well as those of the quick assays, have not answered the pertinent questions: Is DNA alteration obligate in the process? What is the nature of that change induced by agents totally different in their macromolecular interaction that results in malignancy? How is that change induced?

Berenblum, Farber, and others elaborate on the sequences of cellular alteration required for the development of the carcinogenic process. These presentations demonstrate great progress in our attempts to learn the sequence of carcinogenesis. But they also elucidate the second great question in this field, the nature of the cellular alterations induced by the initial changes that evoke malignant behavior. We have come far since Warburg's hypothesis on the nature of the underlying cellular metabolic alterations, and indeed, interest in that hypothesis has appeared again. Still, the obligate cellular alterations remain unknown.

Thus, it should be no surprise that the most important of all the questions that remain unanswered is, what is malignancy?

It has been proposed that if we could identify all the environmental causes of cancer and remove them or modify their effects (with the so-called chemoprotective agents), we could eliminate malignancy. However, we have become increasingly aware that problems in the environment are not simply due to contamination by chemicals (see Becker), and even the most optimistic enthusiast does not envision agents to protect us totally against our environment. The cancer therapist puts forth the thesis that once a "general" cure is found, concern, and indeed experimentation, in the field can cease. However, if we have learned any single lesson in the last half decade, it has been that these studies have enormous potential beyond understanding cancer. Aging, genetic diseases, and many other problems apparently overlap in cause and potential remedies.

More important is the strong possibility that the basic experiments to which I referred above will lead to the final eradication of this dread condition. The cure will be *knowledge*! Thus, while the optimism in each approach can help sustain its protagonists, we must not let this surety place us in adversarial roles. The most certain contribution to the future, to cancer's elimination and to our general understanding of disease, is an understanding of the processes that establish and maintain the normal function and health of the cell.

F.F.B.

Houston

Contents

General Concepts

Cytogenetics 1

PETER C. NOWELL

1. Introduction	3
1.1. Technical Considerations	4
2. Human Leukemias	5
2.1. Chronic Granulocytic Leukemia and the Philadelphia Chromosome	6
2.2. Acute Leukemias	10
2.3. Preleukemic Disorders: Myeloproliferative and Cytopenic	12
2.4. Chronic Lymphocytic Leukemia and Solid Lymphomas	14
3. Human Solid Tumors	17
3.1. Malignant Tumors	18
3.2. Benign and Precancerous Lesions	20
4. Chromosome Breakage and Cancer	21
4.1. Genetic Disorders	21
4.2. Exogenous Agents: Radiation, Chemicals, Viruses	24
5. Cytogenetics of Cells in Culture	28
6. Animal Tumors	29
6.1. Clonal Evolution in Animal Tumors	30
7. Conclusions and Speculations	32
7.1. Chromosome Changes and Tumor Initiation	32
7.2. Chromosome Changes and Tumor Progression	35
7.3. Clinical Applications of Tumor Chromosome Studies	39
8. References	40

1. Introduction	47
2. Speciation and Tumor Formation	48
2.1. Invertebrates	48
2.2. Vertebrates	50
3. Hybridization and Tumor Formation	52
3.1. Hybridization of Species	52
3.2. Hybridization of Strains	53
4. Inbreeding and Occurrence of Tumors	54
4.1. Development of Inbred Strains	54
4.2. Tumor Characteristics of Inbred Strains of Mice	55
4.3. Role of Inbred Strains and Their Hybrids in Cancer Research ...	55
5. Genetics of Spontaneous Tumors	56
5.1. The Threshold Concept in the Inheritance of Cancer	56
5.2. The Somatic Mutation Hypothesis	57
6. Genetics of Chemically Induced Tumors	58
6.1. Pulmonary Tumors in Mice	58
6.2. Subcutaneous Sarcomas in Mice	59
6.3. Selection of Appropriate Strain for Testing Carcinogens	59
7. Genetics of Hormonally Induced Tumors	60
7.1. Mammary Tumors	60
7.2. Hypophyseal Tumors	61
7.3. Adrenocortical Tumors	62
8. Genetics of Virally-Induced Tumors	63
8.1. Inheritance of Susceptibility to the Mammary Tumor Virus	63
8.2. Inheritance of Susceptibility to Leukemia	64
8.3. Genetic Transmission of Tumor Viruses	64
9. References	68

Genetic Influences in Human Tumors 3

ALFRED G. KNUDSON, JR.

1. Introduction	73
2. Genetic States Predisposing to Cancer	74
2.1. Chromosomal Disorders	74
2.2. Mendelian Conditions	75
3. Dominantly Inherited Tumors	77
3.1 Tumor Syndromes	77
3.2. Specific Tumors	79

4. A Mutation Model for Human Cancer	83	xiii
4.1. Initiation in Two or More Steps	83	CONTENTS
4.2. Genetic Consequences	84	
4.3. Role of Environmental Carcinogens	85	
5. Conclusions	86	
6. References	86	

Hormones as Etiological Agents in Neoplasia

4

JACOB FURTH

1. General Considerations	89
1.1. Historical	89
1.2. Nomenclature and Abbreviations	89
1.3. Neoplasia: Basic Defect and Types	91
1.4. Homeostasis (Cybernetics) and Neoplasia	94
1.5. Tumorigenesis by Hormonal Derangement	96
2. The Four Levels Of Communications	99
2.1. Neurohypothalamic Areas and Neoplasia	99
2.2. Cell Types of the Adenohypophysis and Their Neoplasms	101
2.3. Neoplasia in Peripheral Endocrine-Related Organs	103
3. Detection of Hormonal Activity	108
3.1. General Considerations	108
3.2. Detection and Quantitation of Hormones	109
3.3. Steroid vs. Protein Hormones: Their Receptors and Translation of their Messages	110
4. Ectopic Hormones	116
5. Sequential Events: Multiglandular Syndromes	116
5.1. Neonatal Ovariectomy	117
5.2. Thyroidal Carcinogenesis	118
5.3. Multiglandular Diseases	120
6. Problems and Prospects	120
6.1. The Basic Change in Neoplasia	120
6.2. Carcinogenesis without Extrinsic Carcinogens	122
6.3. Relation of Neoplasia to Aging	125
6.4. Prospects	126
7. References	126

Pathogenesis of Plasmacytomas in Mice

5

MICHAEL POTTER

1. Introduction	135
2. "Spontaneous" Plasmacytomas	136

xiv	2.1. Ileocecal Plasmacytomas in Mice	136
CONTENTS	2.2. Ileocecal Immunocytomas in Rats	136
	2.3. Comment	137
	2.4. Plasma Cell Leukemias in Mice	138
	3. Induced Plasmacytomas in Mice	138
	3.1. Plasmacytomagenic Peritoneal Granuloma Inducing Agents	138
	3.2. Genetic Basis of Susceptibility	142
	3.3. The Peritoneal Site	144
	3.4. Role of the Oil Granuloma	146
	3.5. Role of Viruses in Plasmacytoma Development	149
	4. Summary	154
	5. References	155

Immunocompetence and Malignancy 6

CORNELIS J. M. MELIEF AND ROBERT S. SCHWARTZ

1. Introduction	161
2. Deliberate Immunosuppression and Malignancy in Experimental Animals	163
2.1. Immunosuppression and Infection with Oncogenic Viruses	163
2.2. Effects of Immunosuppression on Oncogenesis by Chemicals	165
2.3. Effects of Immunosuppression on Development of Spontaneous Tumors	167
3. Spontaneous Immunosuppression and Malignancy in Experimental Animals	170
3.1. Congenitally Athymic (Nude) Mice	170
3.2. Immunocompetence of Animals with a High Incidence of Tumors	171
3.3. Immunosuppression by Oncogenic Viruses	173
3.4. Immunosuppression by Carcinogenic Chemicals	174
4. Immunosuppression and Malignancy in Human Beings	175
4.1. Immunodeficiency Diseases	175
4.2. Neoplasms in Recipients of Organ Allografts	182
5. Conclusions	186
6. References	189

Epidemiologic Approach to Cancer 7

VINCENT F. GUINEE

1. Introduction	201
2. The Definition of Disease	202
2.1. Classification of a Disease	202

2.2. Definition of a "Case": The Diagnosis of a Disease	202	xv
2.3. Accuracy and Validity	203	CONTENTS
3. The Distribution of Disease—Descriptive Epidemiology	204	
3.1. Incidence and Prevalence	204	
3.2. Age, Sex, Race	206	
3.3. Time	209	
3.4. Geography	211	
3.5. Occupation	212	
4. Identification of Persons with Disease	212	
4.1. Patient Populations	212	
4.2. Case Identification	214	
4.3. Cancer Incidence Surveys	217	
5. Analytic Epidemiology: Research Approach	218	
5.1. Cohort Studies	219	
5.2. Case-Control Studies	219	
6. References	222	
7. Selected General References	223	

Chemical Carcinogenesis

Chemical Agents, the Environment, and the History of Carcinogenesis 8

FREDERICK F. BECKER

1. Introduction	229
2. Laboratory Studies	232
3. Current Problems	234
4. References	238

Metabolism of Chemical Carcinogens 9

J. H. WEISBURGER AND G. M. WILLIAMS

1. Cancer, A Class of Diseases Due Mainly to Environmental Factors: Synthetic or Naturally Occurring	241
2. Types of Chemical Carcinogens	242
2.1. Chemical Carcinogens and Mutagens	249
3. Metabolism of Chemical Carcinogens	250
3.1. Metabolism by Mammalian Enzyme Systems	254

xvi	3.2. Metabolism by Microorganisms	260
CONTENTS	3.3. Chemical Alteration; Endogenous Formation of Carcinogens ...	261
	4. Genotoxic Carcinogens	262
	4.1. Direct-Acting Carcinogens	263
	4.2. Procarcinogens	266
	4.3. Inorganic Carcinogens	298
	5. Epigenetic Carcinogens	299
	5.1. Immunosuppressants	299
	5.2. Hormones	300
	5.3. Cocarcinogens	301
	5.4. Promoters	302
	6. Variation in Carcinogen Metabolism	303
	6.1. Genetic Factors	303
	6.2. Sex and Endocrine Status	304
	6.3. Age	305
	7. Modification of Carcinogen Metabolism	306
	7.1. Diet	307
	7.2. Effect of Mode and Frequency of Exposure	308
	7.3. Effect of Other Agents	309
	8. Concluding Remarks and Prospects	311
	9. References	314

Chemical Carcinogenesis: Interactions of Carcinogens with Nucleic Acids 10

S. RAJALAKSHMI, PREMA M. RAO, AND D. S. R. SARMA

1. Introduction	335
2. Interaction of Chemical Carcinogens with DNA	336
2.1. Covalent Interactions	336
2.2. Noncovalent Interactions	349
2.3. Purine- <i>N</i> -Oxides	351
2.4. Carcinogenic Metals	351
3. Carcinogen-DNA Interactions at the Nucleoprotein Level	351
3.1. Alkylating Agents	353
3.2. Aromatic Amines	354
3.3. Polycyclic Aromatic Hydrocarbons	356
4. Interaction of Chemical Carcinogens with Mitochondrial DNA	357
5. Interaction of Chemical Carcinogens with RNA	359
5.1. General	359
5.2. Alkylating Agents	359
5.3. Aromatic Amines and Amides	362
5.4. Polycyclic Aromatic Hydrocarbons	363

5.5. 4NQO	363	xvii
5.6. AFB ₁	364	CONTENTS
6. Influence of Carcinogen–Nucleic Acid Interaction on the Structure, Synthesis, and Function of DNA and RNA	364	
6.1. Alterations in DNA Structure	364	
6.2. Alterations in DNA Synthesis	366	
6.3. Alterations in RNA Synthesis and Function	367	
7. Carcinogen–DNA Interactions and Carcinogenesis	370	
7.1. Carcinogen–DNA Interactions: Quantitative Analysis	370	
7.2. Carcinogen–DNA Interactions: Qualitative Analysis	372	
7.3. Repair <i>in Vivo</i> of DNA Damage Induced by Chemical Carcinogens	373	
7.4. Probable Steps in the Removal of Bound Carcinogen and Subsequent Repair of the Damaged DNA	377	
7.5. Postreplicative Repair Processes	379	
7.6. DNA Repair and Carcinogenesis	382	
8. Perspectives and Conclusions	384	
9. References	386	

Some Effects of Carcinogens on Cell Organelles

11

DONALD J. SVOBODA AND JANARDAN K. REDDY

1. Introduction	411
1.1. A Brief Review of Acute and Chronic Cytological Effects of Some Common Hepatocarcinogens	412
2. The Carcinogens	415
2.1. Aflatoxins	415
2.2. Azo Compounds	419
2.3. Ethionine	420
2.4. Hypolipidemic Agents	421
2.5. Nitrosamines	425
2.6. Pyrrolizidine Alkaloids	426
2.7. Thioacetamide	428
3. Summary of Response of Organelles to Several Carcinogens	428
3.1. Endoplasmic Reticulum	429
3.2. Plasma Membrane	430
3.3. Mitochondria, Lysosomes, Peroxisomes	432
3.4. Nucleus, Nucleolus	434
4. Selected Site-Specific Models of Carcinogenesis	435
5. References	442